Treatment patterns in UK adult patients with atopic dermatitis treated with systemic immunosuppressants: data from The Health Improvement Network (THIN)
Treatment patterns in UK adult patients with atopic dermatitis treated with systemic immunosuppressants: data from The Health Improvement Network (THIN)
Background: There is limited understanding on patterns of systemic treatment in adults with moderate-to-severe atopic dermatitis (AD) in the UK. Objective: To characterize treatment patterns in adult AD patients prescribed immunosuppressants (IMMs) in the primary care setting. Results: Six hundred and fifty-six patients with AD (6.6%) were prescribed IMM in the analysis (mean age 52.1 years; 59.1% female; age-adjusted Charlson comorbidity index 1.4). Most prevalent (>5%) conditions at baseline were depression (10.8%), contact dermatitis (10.7%), rheumatological disease (7.9%), skin/subcutaneous tissue disorders (6.4%), upper respiratory disease (5.8%), and psoriasis (5.2%). At baseline, up to 50% of patients were prescribed ≥1 IMM. During follow-up, 42.7% of patients were prescribed oral corticosteroids (OCSs), increasing in line with IMM exposure. The most commonly prescribed IMM was methotrexate (43.3%). Ciclosporin, the only approved IMM for AD, was prescribed to 16.9% of patients. Conclusions: The prevalence of comorbidities and high rate of IMM prescriptions demonstrate the impact of AD on quality of life. The frequency of OCS prescribing in AD patients treated with IMMs suggests a lack of disease control with existing therapies, and an unmet need for safe and effective targeted agents for long-term disease control.
Atopic dermatitis, corticosteroids, immunosuppressant, methotrexate
Eckert, Laurent
b2f0cad4-7e41-4327-9514-bf6ca59a9b39
Amand, Caroline
f75e4f7d-593c-42c7-b02c-697f09d86df9
Gadkari, Abhijit
4b4aa735-df51-4d49-b064-c04e3b214f29
Rout, Raj
ddff39c9-fb28-4a08-b249-114ed84e2d20
Hudson, Richard
0dbf191e-a8f1-4933-b31b-147e93d09ef9
Ardern-Jones, Michael
7ac43c24-94ab-4d19-ba69-afaa546bec90
Eckert, Laurent
b2f0cad4-7e41-4327-9514-bf6ca59a9b39
Amand, Caroline
f75e4f7d-593c-42c7-b02c-697f09d86df9
Gadkari, Abhijit
4b4aa735-df51-4d49-b064-c04e3b214f29
Rout, Raj
ddff39c9-fb28-4a08-b249-114ed84e2d20
Hudson, Richard
0dbf191e-a8f1-4933-b31b-147e93d09ef9
Ardern-Jones, Michael
7ac43c24-94ab-4d19-ba69-afaa546bec90
Eckert, Laurent, Amand, Caroline, Gadkari, Abhijit, Rout, Raj, Hudson, Richard and Ardern-Jones, Michael
(2019)
Treatment patterns in UK adult patients with atopic dermatitis treated with systemic immunosuppressants: data from The Health Improvement Network (THIN).
Journal of Dermatological Treatment.
(doi:10.1080/09546634.2019.1639604).
Abstract
Background: There is limited understanding on patterns of systemic treatment in adults with moderate-to-severe atopic dermatitis (AD) in the UK. Objective: To characterize treatment patterns in adult AD patients prescribed immunosuppressants (IMMs) in the primary care setting. Results: Six hundred and fifty-six patients with AD (6.6%) were prescribed IMM in the analysis (mean age 52.1 years; 59.1% female; age-adjusted Charlson comorbidity index 1.4). Most prevalent (>5%) conditions at baseline were depression (10.8%), contact dermatitis (10.7%), rheumatological disease (7.9%), skin/subcutaneous tissue disorders (6.4%), upper respiratory disease (5.8%), and psoriasis (5.2%). At baseline, up to 50% of patients were prescribed ≥1 IMM. During follow-up, 42.7% of patients were prescribed oral corticosteroids (OCSs), increasing in line with IMM exposure. The most commonly prescribed IMM was methotrexate (43.3%). Ciclosporin, the only approved IMM for AD, was prescribed to 16.9% of patients. Conclusions: The prevalence of comorbidities and high rate of IMM prescriptions demonstrate the impact of AD on quality of life. The frequency of OCS prescribing in AD patients treated with IMMs suggests a lack of disease control with existing therapies, and an unmet need for safe and effective targeted agents for long-term disease control.
Text
Treatment patterns in UK adult patients with atopic dermatitis treated with systemic immunosuppressants data from The Health Improvement Network THIN
- Version of Record
More information
Accepted/In Press date: 19 June 2019
e-pub ahead of print date: 15 July 2019
Keywords:
Atopic dermatitis, corticosteroids, immunosuppressant, methotrexate
Identifiers
Local EPrints ID: 432860
URI: http://eprints.soton.ac.uk/id/eprint/432860
ISSN: 0954-6634
PURE UUID: d7463b94-5906-41c0-88ae-33c850d939ec
Catalogue record
Date deposited: 31 Jul 2019 16:30
Last modified: 16 Mar 2024 03:55
Export record
Altmetrics
Contributors
Author:
Laurent Eckert
Author:
Caroline Amand
Author:
Abhijit Gadkari
Author:
Raj Rout
Author:
Richard Hudson
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics